Sequence: RRRRRRRR
| Experiment Id | EXP001993 |
|---|---|
| Paper | Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Trea |
| Peptide | Octaarginine (R8) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | Optimum mass ratio siRNA : GO-PEI-PEG-CPP = 1 : 0.5 (gel retardation screen; GO:PEI ratio 1:60–1:100 gives complete binding at 1:0.5). |
| Formulation Format | GO-PEI-PEG-CPP/siRNA nanocomplex (graphene oxide + PEI + PEG + CPP) |
| Formulation Components | Graphene oxide (GO) + polyethyleneimine (PEI, MW 800) + polyethylene glycol (PEG, MW 2000) + CPP R8, loaded with Rictor siRNA-2 (or Cy5-labeled siRNA for uptake). |
| Size Nm | 231.60 |
| Zeta Mv | 16.10 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | SCID/nude mice bearing MDA-MB-231 xenograft tumors (fat pad injection) |
| Administration Route | Intravenous tail vein injection of siRNA formulations (treatment started 2 weeks after inoculation; monitored 18 days) |
| Output Type | In vivo functional RNA delivery: tumor growth suppression + Ki-67 IHC and TUNEL apoptosis in tumor sections |
| Output Value | GO-PEI-PEG-CPP/siRNA significantly represses tumor growth vs GO-PEI-PEG/siRNA and free siRNA; decreases Ki-67 and increases TUNEL apoptosis in tumors; no major body-weight change. |
| Output Units | |
| Output Notes | Demonstrates functional therapeutic effect in vivo consistent with RNA delivery (Rictor targeting) in TNBC xenograft model. |
| Toxicity Notes | Body weight unaffected across groups during 18-day monitoring. |
| Curation Notes |